National Office of Animal Health
...for the welfare of all animals

Bookmark and Share
 

HOME | NEWS | MEDICINES TOPICS | ABOUT NOAH | BOOKS | CODE | NCAH | LINKS | CONTACT | JOBS | COMPENDIUM | RESPONSIBLE

Topics and Briefing Documents

HEALTH AND WELFARE

CONTROLS ON ANIMAL MEDICINES

ANTIBIOTICS

ANIMALS IN RESEARCH

ORGANOPHOSPHATES

SAFETY OF FOOD & RESIDUES

VACCINES

ADVERTISING

ADVERSE REACTIONS

ENVIRONMENT


CONSUMER ATTITUDES

VETERINARY LEGISLATIVE REVIEW

 

Veterinary medicines in-use shelf life

What is an in-use shelf-life?

An in-use shelf-life is the time period following the first broaching of a container (for example via a needle entering a bung or the unscrewing of a cap) after which any remaining product in the container should be destroyed. Veterinary medicines, human medicines, and increasingly other types of products such as cosmetics and shampoos specify an in-use shelf-life on their labels.

Why is it necessary to have an in-use shelf-life?

An in-use shelf-life is needed to provide assurance of the appropriate quality of the product throughout its use, thereby helping to ensure the safety and efficacy of the product. A product used outside its in-use shelf-life may have insufficient levels of the active substance and this may lead to inefficacy (or in some cases contribute to the development of resistance), or it may contain harmful levels of degradation products, or it may be contaminated with micro-organisms which would further challenge an animal whose health may already be compromised.

Why don’t all medicines have an in-use shelf-life?

Only products which are susceptible to degradation or contamination after first broaching of the pack carry an in-use shelf-life. For example, micro-organisms will not usually survive in non-aqueous environments. Therefore, for a non-aqueous pour-on product which has been shown not to be prone to degradation when exposed to the atmosphere an in-use shelf-life will not be specified.

Why do so many medicines have a 28 day in-use shelf-life?

The in-use shelf-life specified depends on the product, in particular its physical, chemical and microbiological characteristics. The in-use shelf-life is not always 28 days. It may be less than this, for example if the active substance is prone to degradation following exposure to the atmosphere, or it may be longer than this, for example for a product which is very stable and which will not support the growth of micro-organisms (which can be the case for certain oily/non-aqueous injections).

However, many of the multi-dose parenteral (injectable) products do specify a 28 day maximum in-use shelf-life. The main reason for this is that the EU guidelines for veterinary and human medicines** on the “maximum shelf-life for sterile veterinary products after first opening or following reconstitution” both indicate that, from a microbiological point of view, for aqueous preserved sterile products and non-aqueous sterile products the in-use shelf-life should not normally exceed 28 days. There are examples of oily injections in the UK where the in-use shelf-life exceeds 28 days. In these instances the company has conducted additional microbial challenge studies beyond those set out in the European Pharmacopoeia.

Is it possible to extend an in-use shelf-life?

Marketing Authorisation Holders (the companies who produce the product) can apply to the regulatory body who approve veterinary medicines, The Veterinary Medicines Directorate, in some circumstances to vary their authorisation to permit a longer in-use shelf-life. However, there will be significant additional costs involved in generating the data and significant costs involved in making the changes.

Can smaller pack sizes be produced by companies?

Another option to try to avoid wastage of medicines would be for Marketing Authorisation Holders to produce smaller pack sizes, but again this will involve varying the authorisation and is likely to involve the need for the generation of further data, with the inevitable additional costs that this involves. In the past medicines where manufacturers had both large and small pack sizes on the market, a frequent problem that was encountered was that the smaller packs were not purchased and used by vets who were attempting to make savings based on economies of scale. As a result, the smaller pack sizes were discontinued.

**(EMEA/CVMP/198/99 and CPMP/QWP/159/96 respectively)

Note- this NOAH briefing document is based on the contents of a VMD document addressing the same issue. The full VMD document can be accessed via the following link- http://www.vmd.gov.uk/VetSQP/In_use_shelf_life.pdf

September 2010

PRINTER-FRIENDLY COPY OF THIS DOCUMENT

HOME | NEWS | MEDICINES TOPICS | ABOUT NOAH | BOOKS | CODE | NCAH | LINKS | CONTACT | JOBS | COMPENDIUM | RESPONSIBLE


Bookmark and Share